T-cell intracellular antigens function as tumor suppressor genes

Cell Death and Disease

Volumn 6, Issue 3, 2015, Pages

  Sanchez Jimenez C ^a   Ludena M D ^b   Izquierdo, J M ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; DOXYCYCLINE; INITIATION FACTOR 2; MESSENGER RNA PRECURSOR; PROTEIN P53; T CELL INTRACELLULAR ANTIGEN 1; T CELL INTRACELLULAR ANTIGEN RECEPTOR; TETRACYCLINE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; POLYADENYLIC ACID BINDING PROTEIN; RNA BINDING PROTEIN; TIA1 PROTEIN, HUMAN; TIAL1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER PROGNOSIS; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ECTOPIC EXPRESSION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; RNA SPLICING; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; SQUAMOUS CELL LUNG CARCINOMA; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; ANIMAL; CELL CYCLE; CELL LINE; DRUG SCREENING; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOPRECIPITATION; METABOLISM; NUDE MOUSE; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL DEATH; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MICE; MICE, NUDE; POLY(A)-BINDING PROTEINS; RNA-BINDING PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84988847772     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.43     Document Type: Article

References (53)

1. Tian Q, Streuli M, Saito H, Schlossman SF, Anderson P. A polyadenylate binding protein localized to the granules of cytolytic lymphocytes induces DNA fragmentation in target cells. Cell 1991; 67: 629-639.
2. Kawakami A, Tian Q, Duan X, Streuli M, Schlossman SF, Anderson P. Identification and functional characterization of a TIA-1-related nucleolysin. Proc Natl Acad Sci USA 1992; 89: 8681-8685.
3. Ray D, Kazan H, Cook KB, Weirauch MT, Najafabadi HS, Li X et al. A compendium of RNA-binding motifs for decoding gene regulation. Nature 2013; 499: 172-177.
4. Suswam EA, Li YY, Mahtani H, King PH. Novel DNA-binding properties of the RNA-binding protein TIAR. Nucleic Acids Res 2005; 33: 4507-4518.
5. McAlinden A, Liang L, Mukudai Y, Imamura T, Sandell LJ. Nuclear protein TIA1 regulates COL2A1 alternative splicing and interacts with precursor mRNA and genomic DNA. J Biol Chem 2007; 282: 24444-24454.
6. Das R, Yu J, Zhang Z, Gygi MP, Krainer AR, Gygi SP et al. SR proteins function in coupling RNAP II transcription to pre-mRNA splicing. Mol Cell 2007; 26: 867-881.
7. Del Gatto-Konczak F, Bourgeois CF, Le Guiner C, Kister L, Gesnel MC, Stévenin J et al. The RNA-binding protein TIA1 is a novel mammalian splicing regulator acting through intron sequences adjacent to a 5' splice site. Mol Cell Biol 2000; 20: 6287-6299.
8. Förch P, Puig O, Kedersha N, Martínez C, Granneman S, Séraphin B et al. The apoptosispromoting factor TIA1 is a regulator of alternative pre-mRNA splicing. Mol Cell 2000; 6: 1089-1098.
9. Izquierdo JM, Majós N, Bonnal S, Martínez C, Castelo R, Guigó R et al. Regulation of Fas alternative splicing by antagonistic effects of TIA1 and PTB on exon definition. Mol Cell 2005; 19: 475-484.
10. Izquierdo JM, Valcárcel J. Two isoforms of the T-cell intracellular antigen 1 (TIA-1) splicing factors display distinct splicing regulation activities. Control of TIA-1 isoform ratio by TIA-1 related protein. J Biol Chem 2007; 282: 19410-19417.
11. Wang Z, Kayikci M, Briese M, Zarnack K, Luscombe NM, Rot G et al. iCLIP predicts the dual splicing effects of TIA-RNA interactions. PLoS Biol 2010; 8: E1000530.
12. López de Silanes I, Galbán S, Martindale JL, Yang X, Mazan-Mamczarz K, Indig FE et al. Identification and functional outcome of mRNAs associated with RNA-binding protein TIA1. Mol Cell Biol 2005; 25: 9520-9531.
13. Mazan-Mamczarz K, Lal A, Martindale JL, Kawai T, Gorospe M. Translational repression by RNA-binding protein TIAR. Mol Cell Biol 2006; 26: 2716-2727.
14. Kim HS, Kuwano Y, Zhan M, Pullmann Jr R, Mazan-Mamczarz K, Li H et al. Elucidation of a C-rich signature motif in target mRNAs of RNA-binding protein TIAR. Mol Cell Biol 2007; 27: 6806-6817.
15. Yamasaki S, Stoecklin G, Kedersha N, Simarro M, Anderson P. T-cell intracellular antigen-1 (TIA1)-induced translational silencing promotes the decay of selected mRNAs. J Biol Chem 2007; 282: 30070-30077.
16. Piecyk M, Wax S, Beck AR, Kedersha N, Gupta M, Maritim B et al. TIA1 is a translational silencer that selectively regulates the expression of TNF-αlpha. EMBO J 2000; 19: 4154-4163.
17. Liao B, Hu Y, Brewer G. Competitive binding of AUF1 and TIAR to MYC mRNA controls its translation. Nat Struct Mol Biol 2007; 14: 511-518.
18. Reyes R, Alcalde J, Izquierdo JM. Depletion of T-cell intracellular antigen (TIA)-proteins promotes cell proliferation. Genome Biol 2009; 10: R87.
19. Damgaard CK, Lykke-Andersen J. Translational coregulation of 5'TOP mRNAs by TIA-1 and TIAR. Genes Dev 2011; 25: 2057-2068.
20. Gottschald OR, Malec V, Krasteva G, Hasan D, Kamlah F, Herold S et al. TIAR and TIA1 mRNA-binding proteins co-aggregate under conditions of rapid oxygen decline and extreme hypoxia and suppress the HIF-1a pathway. J Mol Cell Biol 2010; 2: 345-356.
21. Izquierdo JM, Alcalde J, Carrascoso I, Reyes R, Ludeña MD. Knockdown of T-cell intracellular antigens triggers cell proliferation, invasion and tumor growth. Biochem J 2011; 435: 337-344.
22. Sánchez-Jiménez C, Carrascoso I, Barrero J, Izquierdo JM. Identification of a set of miRNAs differentially expressed in transiently TIA-depleted HeLa cells by genome-wide profiling. BMC Mol Biol 2013; 14: 4.
23. Beck AR, Miller JJ, Anderson P, Streuli M. RNA-binding protein TIAR is essential for primordial germ cell development. Proc Natl Acad Sci USA 1988; 95: 2331-2336.
24. Kharraz Y, Salmand PA, Camus A, Auriol J, Gueydan C, Kruys V, Morello D. Impaired embryonic development in mice overexpressing the RNA-binding protein TIAR. PLoS One 2010; 5: E11352.
25. Sánchez-Jiménez C, Izquierdo JM. T-cell intracellular antigen (TIA)-proteins deficiency in murine embryonic fibroblast alters cell-cycle progression and induces autophagy. PLoS One 2013; 8: E75127.
26. Carrascoso I, Sánchez-Jiménez C, Izquierdo JM. Genome-wide profiling reveals a role for T-cell intracellular antigens TIA1 and TIAR in the control of translational specificity in HeLa cells. Biochem J 2014; 461: 43-50.
27. Izquierdo JM. Hu antigen R (HuR) functions as an alternative pre-mRNA splicing regulator of Fas apoptosis-promoting receptor on exon definition. J Biol Chem 2008; 283: 19077-19084.
28. Izquierdo JM. Heterogeneous ribonucleoprotein C displays a repressor activity mediated by T-cell intracellular antigen-1-related/like protein to modulate Fas exon 6 splicing through a mechanism involving Hu antigen R. Nucleic Acids Res 2010; 38: 8001-8014.
29. Al-Ahmadi W, Al-Ghamdi M, Al-Haj L, Al-Saif M, Khabar KS. Alternative polyadenylation variants of the RNA binding protein, HuR: Abundance, role of AU-rich elements and auto-regulation. Nucleic Acids Res 2009; 37: 3612-3624.
30. Le Guiner C, Lejeune F, Galiana D, Kister L, Breathnach R, Stévenin J et al. TIA-1 and TIAR activate splicing of alternative exons with weak 5' splice sites followed by a U-rich stretch on their own pre-mRNAs. J Biol Chem 2001; 276: 40638-40646.
31. Wang W, Caldwell MC, Lin S, Furneaux H, Gorospe M. HuR regulates cyclin A and cyclin B1 mRNA stability during cell proliferation. EMBO J 2000; 19: 2340-2350.
32. Abdelmohsen K, Gorospe M. Posttranscriptional regulation of cancer traits by HuR. Wiley Interdiscip Rev RNA 2010; 1: 214-229.
33. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9: 402-412.
34. Kruse J, Gu W. Modes of p53 regulation. Cell 2009; 137: 609-622.
35. Singer S, Zhao R, Barsotti AM, Ouwehand A, Fazollahi M, Coutavas E et al. Nuclear pore component Nup98 is a potential tumor suppressor and regulates posttranscriptional expression of select p53 target genes. Mol Cell 2012; 48: 799-810.
36. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
37. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 1995; 9: 935-944.
38. Carvajal LA, Manfredi JJ. Another fork in the road-life or death decisions by the tumor suppressor p53. EMBO Rep 2013; 14: 414-421.
39. Anderson P, Kedersha N. RNA granules: Post-transcriptional and epigenetic modulators of gene expression. Nat Rev Mol Cell Biol 2009; 10: 430-436.
40. Kalverda B, Pickersgill H, Shloma VV, Fornerod M. Nucleoporins directly stimulate expression of developmental and cell-cycle genes inside the nucleoplasm. Cell 2010; 140: 360-371.
41. Reinhardt HC, Cannell IG, Morandell S, Yaffe MB. Is post-transcriptional stabilization, splicing and translation of selective mRNAs a key to the DNA damage response? Cell Cycle 2011; 10: 23-27.
42. Montecucco A, Biamonti G. Pre-mRNA processing factors meet the DNA damage response. Front Genet 2013; 4: 102.
43. Gonzalez-Pérez A, Pérez-Llamas C, Deu-Pons J, Tamborero D, Schroeder MP, Jene-Sanz A et al. IntOGen-mutations identifies cancer drivers across tumor types. Nat Methods 2013; 10: 1081-1082.
44. Yang C, Romaniuk PJ. The ratio of +/-KTS splice variants of the Wilms' tumour suppressor protein WT-1 mRNA is determined by an intronic enhancer. Biochem Cell Biol 2008; 86: 312-321.
45. Zhu H, Hinman MN, Hasman RA, Mehta P, Lou H. Regulation of neuron-specific alternative splicing of neurofibromatosis type 1 pre-mRNA. Mol Cell Biol 2008; 28: 1240-1251.
46. Wang E, Miller LD, Ohnmacht GA, Mocellin S, Perez-Díez A, Petersen D et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002; 62: 3581-3586.
47. Mocellin S, Provenzano M, Lise M, Nitti D, Rossi CR. Increased TIA-1 gene expression in the tumor microenvironment after locoregional administration of tumor necrosis factor-alpha to patients with soft tissue limb sarcoma. Int J Cancer 2003; 107: 317-322.
48. Asano N, Suzuki R, Matsuo K, Kagami Y, Ishida F, Tamaru JI et al. Cytotoxic molecule exp ression is predictive of prognosis in Hodgkin's-like anaplastic large cell lymphoma. Histopathology 2007; 50: 705-715.
49. Zlobec I, Karamitopoulou E, Terracciano L, Piscuoglio S, Iezzi G, Muraro MG et al. TIA-1 cytotoxic granule-associated RNA binding protein improves the prognostic performance of CD8 in mismatch repair-proficient colorectal cancer. PLoS One 2010; 5: E14282.
50. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2012; 62: 10-29.
51. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998; 19: 348-355.
52. HakemR, de la Pompa JL, Sirard C, Mo R, Woo M, HakemA et al. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 1996; 85: 1009-1023.
53. Hamdollah Zadeh MA, Amin EM, Hoareau-Aveilla C, Domingo E, Symonds KE, Ye K et al. Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance. Mol Oncol 2015; 9: 167-178.